NouBio
Develops animal-free media and carriers for scalable cell culture in cultivated meat, cell therapy, and vaccine production, reducing costs by up to 95% compared to traditional fetal bovine serum.
- CEO / Founder
- Stephen Gerard Gray
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $200K
- Latest Round
- Pre-Seed
- Key Investors
- Big Idea Ventures
Technology & Products
Key Products
NouSerum (FBS replacement); Animal-free media for cell culture; Carriers for scalable cell culture
Technological Advantage
Claimed: 95% cost reduction in media costs; verified: Listed in AM directories (VoxelMatters) as bioprinting company; defensible through proprietary formulations (patent status unclear).
Differentiation
Value Proposition
Reduces cell-based biomanufacturing costs by 95% vs. traditional FBS, enables scalable production with biodegradable/edible materials, and aims to lower cultivated meat costs to $12/kg.
How They Differentiate
Focuses on animal-free media for cell culture vs. competitors in cultivated fats or 3D tissue engineering; claims 95% cost reduction in media vs. traditional FBS, targeting broader biomanufacturing applications.
Market & Competition
Target Customers
Cultivated meat producers, cell therapy companies, vaccine manufacturers, synthetic biology firms
Industry Verticals
Cellular Agriculture; Biotechnology; Pharmaceuticals; Food Tech
Competitors
Cultimate; ImpacFat; Ouro Foods
Growth & Milestones
Growth Metrics
Tested by over 30 users in 1 year for different cell-based industries; 3 total employees
Major Milestones
Founded in 2022; Backed by Big Idea Ventures; Aims to reduce cultivated meat costs to $12/kg